SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sylvester RJ, van der Meijden APM, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a combined analysis of the published results of randomized clinical trials. J Urol. 2002; 168: 1964-1970.
  • 2
    Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology. 2004; 63: 682-686.
  • 3
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol. 2003; 169: 90-95.
  • 4
    Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006; 49: 790-797.
  • 5
    Sylvester RJ, van der Meijden APM, Witjes JA, Kurth KH. Bacillus Calmette-Guerin versus chemotherapy in the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005; 174: 86-92.
  • 6
    Huguet J, Crego M, Sabate S, Salvador J, Palou J, Villavicencio H. Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol. 2005; 48: 53-59.
  • 7
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008; 54: 303-314.
  • 8
    Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol. 2003; 169: 1706-1708.
  • 9
    Joudi FN, O'Donnell MA. Second-line intravesical therapy versus cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol. 2004; 14: 271-275.
  • 10
    El Karak F, Flechon A. Gemcitabine in bladder cancer. Expert Opin Pharmacother. 2007; 8: 3251-3256.
  • 11
    Gontero P, Marini L, Frea B. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option. BJU Int. 2005; 96: 970-976.
  • 12
    Dalbagni G, Russo P, Sheinfeld J, et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol. 2002; 20: 3193-3198.
  • 13
    Dalbagni G, Russo P, Bochner B, et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol. 2006; 24: 2729-2734.
  • 14
    Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from 7 EORTC trials. Eur Urol. 2006; 49: 466-475.
  • 15
    Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-181.
  • 16
    Morabito F, Rossi R, Graziano ME, et al. Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance. Arch Ital Urol Androl. 2006; 78: 1-4.
  • 17
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 18
    Sarosdy MF, Manyak MJ, Sagalowsky AI, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guerin. Urology. 1998; 5: 226-231.
  • 19
    O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol. 2004; 172: 888-893.
  • 20
    Van Der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol. 2004; 46: 65-72.
  • 21
    Waidelich R, Stepp H, Baumgartner R, Weninger E, Hofstetter A, Kriegmair M. Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer. J Urol. 2001; 165: 1904-1907.
  • 22
    Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. J Urol. 2000; 163: 761-767.
  • 23
    Bartoletti R, Cai T, Gacci M, et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology. 2005; 66: 726-731.
  • 24
    Gacci M, Bartoletti R, Cai T, et al. Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study. Urol Int. 2006; 76: 106-111.
  • 25
    Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer. 2007; 97: 1499-1504.
  • 26
    Gontero P, Frea B. Actual experience and future development of gemcitabine in superficial bladder cancer. Ann Oncol. 2006; 17( suppl 5): 123-128.
  • 27
    Hendricksen K, Witjes JA. Intravesical gemcitabine: an update of clinical results. Curr Opin Urol. 2006; 16: 361-366.
  • 28
    Bassi P, De Marco V, Tavolini IM, et al. Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guerin therapy. Urol Int. 2005; 75: 309-313.